Schrödinger to Participate in Upcoming Investor Conferences
Schrödinger (SDGR) has announced its management's participation in three major investor conferences in March 2025. The company will be featured in fireside chat sessions at the following events:
• TD Cowen 45th Annual Health Care Conference on March 4 at 10:30 a.m. ET
• Leerink Partners Global Biopharma Conference on March 10 at 3:40 p.m. ET
• KBCM Healthcare Forum on March 18 at 9:00 a.m. ET
All discussions will be accessible through the Investors section of Schrödinger's website and will remain available for approximately 90 days after each event.
Schrödinger (SDGR) ha annunciato la partecipazione della sua direzione a tre importanti conferenze per investitori nel marzo 2025. L'azienda sarà presente in sessioni di chat informali ai seguenti eventi:
• 45ª Conferenza Annuale sulla Salute di TD Cowen il 4 marzo alle 10:30 ET
• Conferenza Globale Biopharma di Leerink Partners il 10 marzo alle 15:40 ET
• Forum Sanitario KBCM il 18 marzo alle 9:00 ET
Tutte le discussioni saranno accessibili attraverso la sezione Investitori del sito web di Schrödinger e rimarranno disponibili per circa 90 giorni dopo ciascun evento.
Schrödinger (SDGR) ha anunciado la participación de su dirección en tres importantes conferencias para inversores en marzo de 2025. La empresa estará presente en sesiones de charla informal en los siguientes eventos:
• 45ª Conferencia Anual de Salud de TD Cowen el 4 de marzo a las 10:30 a.m. ET
• Conferencia Global Biopharma de Leerink Partners el 10 de marzo a las 3:40 p.m. ET
• Foro de Salud KBCM el 18 de marzo a las 9:00 a.m. ET
Todas las discusiones estarán accesibles a través de la sección de Inversores del sitio web de Schrödinger y estarán disponibles durante aproximadamente 90 días después de cada evento.
슈뢰딩거 (SDGR)는 2025년 3월에 있을 세 가지 주요 투자자 회의에 경영진이 참여한다고 발표했습니다. 회사는 다음 이벤트에서 화상 대화 세션에 참석할 예정입니다:
• TD Cowen 제45회 연례 헬스케어 회의 3월 4일 오전 10:30 ET
• Leerink Partners 글로벌 바이오파마 회의 3월 10일 오후 3:40 ET
• KBCM 헬스케어 포럼 3월 18일 오전 9:00 ET
모든 논의는 슈뢰딩거 웹사이트의 투자자 섹션을 통해 접근 가능하며 각 이벤트 후 약 90일 동안 제공됩니다.
Schrödinger (SDGR) a annoncé la participation de sa direction à trois grandes conférences pour investisseurs en mars 2025. L'entreprise sera présente lors de sessions de discussion informelles lors des événements suivants :
• 45e Conférence Annuelle sur la Santé de TD Cowen le 4 mars à 10h30 ET
• Conférence Biopharma Mondiale de Leerink Partners le 10 mars à 15h40 ET
• Forum de Santé KBCM le 18 mars à 9h00 ET
Toutes les discussions seront accessibles via la section Investisseurs du site web de Schrödinger et resteront disponibles pendant environ 90 jours après chaque événement.
Schrödinger (SDGR) hat die Teilnahme des Managements an drei wichtigen Investorenkonferenzen im März 2025 angekündigt. Das Unternehmen wird in informellen Gesprächsrunden bei den folgenden Veranstaltungen vertreten sein:
• 45. jährliche Gesundheitskonferenz von TD Cowen am 4. März um 10:30 Uhr ET
• Globale Biopharma-Konferenz von Leerink Partners am 10. März um 15:40 Uhr ET
• KBCM Gesundheitsforum am 18. März um 9:00 Uhr ET
Alle Diskussionen sind über den Bereich Investoren auf der Website von Schrödinger zugänglich und bleiben etwa 90 Tage nach jeder Veranstaltung verfügbar.
- None.
- None.
- TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T.
- Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T.
- KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T.
The live discussions can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224832431/en/
Allie Nicodemo
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325
Source: Schrödinger
FAQ
When is Schrödinger (SDGR) presenting at the TD Cowen Healthcare Conference in 2025?
What investor conferences is SDGR attending in March 2025?
How long will SDGR's conference presentations be available for viewing?
Where can investors access SDGR's March 2025 conference presentations?
